Maintenance Notice (3:30 - 8:30 AM June 28, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Life Science News June 2025 | [TCIPracticalExample] Goldberg Amination Using... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 212322-56-0 | 产品编码: E1033
Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate
![Chemical Structure of Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate](/medias/E1033.jpg?context=bWFzdGVyfHJvb3R8NDEwNjR8aW1hZ2UvanBlZ3xhREJpTDJnMU5TODRPVEl4TmpFNE56RXdOVFU0TDBVeE1ETXpMbXB3Wnd8NmU1YTNkOWVlYmI2MjkyYjQwMGIxNjU4MmZiNmJmYjAxNDgxODZhYTRiMmVjOTc3NDQxMGQwNDZlYzczNjJlYg "Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate")
![Thumbnail of Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate](/medias/E1033.jpg?context=bWFzdGVyfHJvb3R8MTM0MDl8aW1hZ2UvanBlZ3xhR1JoTDJoaU1TODRPVE0xTURjME5EazJOVFF5TDBVeE1ETXpMbXB3Wnd8YzEzZDlmYzVlMGIyOWIxZTI1YjYyZDA4YTdmNDM1NWMyY2M3MzdmMDAzZmZmYWFhZGVhZjBiYTViYjlmMjg3Yg)
×
![]()
×
![Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate](/_ui/responsive/theme-tci/images/missing_product_zoom.jpg "Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate")
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 104.0 to 108.0 °C |
物性（参考值）
| 熔点 | 106 °C |
| 溶解性（可溶于） | 甲醇 |
GHS
相关法规
运输信息
| HS编码* | 2933.39-000 |
应用
A Synthetic Intermediate of Dabigatran and Its Derivatives
This product has been used as a synthetic intermediate of dabigatran [D5902, D5904 (Etexilate)] and its derivatives, which are direct thrombin inhibitors.
References
- Structure-based design of novel potent nonpeptide thrombin inhibitors
- Synthesis, characterization and suppression of impurities during optimization of Dabigatran etexilate
- Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors
- Gradient RP-HPLC method for the determination of potential impurities in dabigatran etexilate in bulk drug and capsule formulations
参考文献
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。